Angiotensin Neprilysin Inhibition for Patients With Heart Failure

Milton Packer

doi:10.1001/jamacardio.2016.3053

September 21, 2016JAMA Cardiology

Angiotensin Neprilysin Inhibition for Patients With Heart Failure

View at Publisher

Ask AI

Bookmark

Share

Key Points

To evaluate the pharmacological mechanism, clinical efficacy, and therapeutic role of dual angiotensin receptor and neprilysin inhibition in heart failure management.
Synthesized clinical trial evidence and pharmacological data evaluating angiotensin neprilysin inhibitor therapy in heart failure populations.
Assessed cardiovascular hemodynamics, neurohormonal regulation, and clinical outcomes associated with dual pathway inhibition.
Dual inhibition simultaneously suppresses the renin-angiotensin system and preserves endogenous vasoactive peptides, promoting vasodilation and natriuresis.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Reviews angiotensin neprilysin inhibition in patients with heart failure, highlighting its therapeutic potential in improving cardiovascular outcomes.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Milton Packer (2016) studied this question.

synapsesocial.com/papers/6a704570af0c21e939281b75 https://doi.org/10.1001/jamacardio.2016.3053

View at Publisher

Ask AI

Bookmark

Share

Angiotensin Neprilysin Inhibition for Patients With Heart Failure

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Angiotensin Neprilysin Inhibition for Patients With Heart Failure

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Keep reading

Keep reading